Ads
related to: Psoriatic Arthritis- Scalp Psoriasis Results
View Clinical Trial Information For
a Scalp Psoriasis Therapy Option.
- Safety & Risk Factor Info
View Metabolic Syndrome Risk Info
For a Psoriasis Treatment Option.
- Biologic MOA for PsO
Learn More About the MOA for this
Plaque Psoriasis Treatment.
- Clinical Studies
Review Clinical Trial Results for
a Plaque Psoriasis Treatment.
- HCP Dosing Resources
View Treatment Options For Moderate
to Severe Plaque Psoriasis.
- Safety & Prescribing Info
View Safety & Prescription Info for
a Plaque Psoriasis Treatment.
- Scalp Psoriasis Results
Search results
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 4 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
Studies Show Linked Biological Pathways Driving Skin Inflammation
WFRV 5 Green Bay· 3 days agoA certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies ...
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
ETF DAILY NEWS· 4 days agoPanagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure ...
Marathon Capital Management Has $4.48 Million Holdings in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 4 days agoMarathon Capital Management grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with ...
Zacks Research Weighs in on AbbVie Inc.’s FY2024 Earnings (NYSE:ABBV)
ETF DAILY NEWS· 7 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at Zacks Research raised their FY2024 EPS estimates for AbbVie in a note issued to investors on Tuesday, May 14th. Zacks Research analyst ...
AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program
FierceBiotech· 3 days agoAltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...
Johnson & Johnson (NYSE:JNJ) Shares Bought by BI Asset Management Fondsmaeglerselskab A S
ETF DAILY NEWS· 3 days agoBI Asset Management Fondsmaeglerselskab A S lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 59.0% in the 4th quarter, according to the company in its most recent 13F filing ...
Johnson & Johnson (NYSE:JNJ) Position Reduced by Main Street Financial Solutions LLC
ETF DAILY NEWS· 2 days agoMain Street Financial Solutions LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% during the fourth quarter, according to its most recent Form 13F filing ...
Robeco Institutional Asset Management B.V. Sells 501,987 Shares of Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 18 hours agoRobeco Institutional Asset Management B.V. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 41.0% during the fourth quarter, according to its most recent 13F filing with the ...
Dynamic Technology Lab Private Ltd Reduces Stake in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 3 days agoDynamic Technology Lab Private Ltd decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 59.3% during the 4th quarter, according to the company in its most recent ...
Ad
related to: Psoriatic Arthritis